Menu
Menu
Question:
Can you tell me more about the OIG’s recommendation to strengthen oversight of Part D payments for compounded topical drugs?
Answer:
According to The Solutions to Reduce Fraud, Waste, and Abuse in HHS Programs: OIG’s Top Recommendations 2019 compendium, “CMS issued a memorandum to plan sponsors that clarified Part D policies for coverage of compounded topical drugs and use of utilization management tools.” The agency did some pharmacy analysis but has yet to give limited training for plan sponsors on compounded topical drugs. This is in part because CMS has yet to complete follow-ups for pharmacy and prescribers that were identified by the Office of the Inspector General (OIG).
CPT® copyright 2023 American Medical Association (AMA). All rights reserved.
Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
CPT is a registered trademark of the American Medical Association.
Subscribe to receive our News, Insights, and Compliance Question of the Week delivered right to your inbox.
Address: 5874 Blackshire Path, #13, Inver Grove Heights, MN 55076
Phone: (800) 252-1578
Email: support@medlearnmedia.com
Hours: 9am – 5pm CT
Copyright © 2024 MedLearn Publishing. Powered by MedLearn Media.
Happy World Health Day! Our exclusive webcast, ‘2024 SDoH Update: Navigating Coding and Screening Assessment,’ is just $99 for a limited time! Use code WorldHealth24 at checkout.